• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 2: Rational Drug Use

Article

While formularies should provide physicians the ability to treat any patient that walks into the office, there also need to be clinical exceptions that allow patients with mitigating circumstances to get any product clinically necessary.

While formularies should provide physicians the ability to treat any patient that walks into the office, there also need to be clinical exceptions that allow patients with mitigating circumstances to get any product clinically necessary, said Steven Miller, MD, MBA.

“Clearly doctors and patients would like unfettered access to all products, but we know that the economic reality resulting in that would be much, much higher drug costs,” he said.

Keith Hoffman, Phd, would like to see more analysis of post-marketing adverse event data included in formulary decisions.

“The ramifications for patient safety are not all the way figured out prior to the release of the drugs,” he explained.

Related Videos
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Dr Brian Mulherin
Dr Brian Mulherin
Lindsey Valenzuela, PharmD, APh, BCACP - screenshot by AJMC
Robert Andrews, former US representative for New Jersey and CEO of the Health Transformation Alliance
Robert Andrews, chief executive officer, Health Transformation Alliance
Dr David Kuter
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.